Cosmos Health Secures EU Distribution Rights for Virax Biolabs’ Mpox Virus Real-Time PCR Detection Kits

In a significant development, Cosmos Health Inc. (NASDAQ: COSM), a Chicago-based healthcare company, has announced that it holds exclusive rights to distribute MPox virus Real-Time PCR detection kits in Greece and Cyprus, along with non-exclusive distribution rights across Europe. This follows an agreement with UK-based diagnostics company Virax Biolabs (NASDAQ: VRAX). The World Health Organization (WHO) has declared the MPox outbreak in the Democratic Republic of Congo and other African countries as a public health emergency of international concern. On August 15, 2024, Sweden became the first country outside of Africa to confirm a new MPox strain, further escalating the urgency of effective diagnostic measures.

Greg Siokas, CEO of Cosmos Health, emphasized the company’s readiness to support governments and public health authorities in the EU/EEA as MPox cases emerge in Europe. This partnership with Virax Biolabs positions Cosmos Health at the forefront of viral disease detection and prevention, a critical need given the rapid spread of MPox. Founded in 2013, Virax Biolabs specializes in the prevention, detection, and diagnosis of viral diseases, focusing particularly on immunology. Their MPox test is designed for rapid diagnosis from human serum and lesion exudate specimens, providing preliminary results that require clinical correlation with patient history and other diagnostic information.

Cosmos Health Inc. is a globally renowned, vertically integrated healthcare group with a diverse portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, Bio-Bebe, and C-Sept. Through its subsidiary Cana Laboratories S.A., Cosmos Health manufactures a wide range of healthcare products, including pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes an extensive array of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors in Greece and the UK.

In addition to its manufacturing and distribution capabilities, Cosmos Health has established several research and development (R&D) partnerships targeting major health disorders such as obesity, diabetes, and cancer. The company specializes in developing novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Furthermore, Cosmos Health has expanded its reach into the telehealth market through the acquisition of ZipDoctor, Inc., a Texas-based telehealth company. This strategic move aims to broaden the company’s distribution network across Europe, Asia, and North America.

The company’s operational infrastructure includes offices and distribution centers located in Thessaloniki and Athens, Greece, as well as Harlow, UK. For more detailed information about the company’s activities and offerings, interested parties can visit their official websites and social media profiles. The comprehensive reach and diversified portfolio of Cosmos Health underscore its commitment to enhancing public health and addressing emerging healthcare challenges on a global scale.

It is important to note that the matters discussed in this article contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may include words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘intends,’ ‘projects,’ ‘estimates,’ ‘plans,’ and similar expressions, or future or conditional verbs such as ‘will,’ ‘should,’ ‘would,’ ‘may,’ and ‘could.’ These forward-looking statements involve unknown risks and uncertainties that could materially impact the topics discussed in this article for various reasons outside the company’s control.

Such risks and uncertainties include the company’s ability to raise sufficient financing to execute its business plans, regain compliance with NASDAQ listing requirements, and manage the effects of the COVID-19 pandemic and the war in Ukraine on its operations and the global economy. Readers are advised to review the risk factors highlighted in the company’s filings with the Securities and Exchange Commission (SEC), available on the SEC’s website. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Press releases are a vital tool for businesses and organizations to communicate important information to the public. They are typically used to announce new products or services, share company news, or respond to crises or events. Press releases follow a specific format and are distributed to various media outlets, such as newspapers, magazines, and online news sites. By submitting a press release, companies can gain exposure and reach a wider audience. Press releases should be concise and to the point, with a catchy headline and engaging content. They should provide all the necessary information in the first paragraph, including the who, what, when, where, and why of the release.

Quotes from key individuals can add credibility and interest to a press release. It is essential to avoid excessive use of jargon and technical language, as press releases are intended to be easily understood by a general audience. Including multimedia, such as images or videos, can make a press release more visually appealing and increase the chances of it being picked up by media outlets. It is crucial to research and target the appropriate media outlets for each press release, as well as individual journalists or reporters who may be interested in the topic. Press releases can also be submitted through press release distribution services, which help to reach a wider audience and improve search engine visibility.

Proofreading and editing are critical to ensure the press release is error-free and presents a professional image of the company. Press releases should be timely and newsworthy, as journalists are more likely to cover a story that is current and relevant. In addition to reaching media outlets, press releases can also be shared on social media and company websites to reach a broader audience. Press releases can be an effective way to increase brand awareness and establish a company as an authority in its industry. They can also provide valuable backlinks to a company’s website, which can improve search engine rankings.

Tracking the success of press releases through media coverage and website traffic is essential to determine their effectiveness. Press releases should be a part of a larger public relations strategy, working in conjunction with other communication channels. Businesses and organizations should always have a trained spokesperson available to speak to media outlets and answer any questions that may arise from a press release. By utilizing press releases effectively, companies can keep the public informed and maintain a positive reputation in the eyes of the media and their audience.

In the context of the current global health landscape, the role of diagnostic tools like the MPox virus Real-Time PCR detection kits becomes even more critical. Rapid and accurate diagnosis is paramount in controlling the spread of infectious diseases. The collaboration between Cosmos Health and Virax Biolabs is a testament to the importance of strategic partnerships in addressing public health emergencies. With the exclusive distribution rights in Greece and Cyprus and non-exclusive rights across Europe, Cosmos Health is well-positioned to make a significant impact in the fight against MPox.

The ongoing efforts of Cosmos Health to expand its product offerings and enhance its distribution network highlight the company’s commitment to innovation and excellence in healthcare. By leveraging its expertise in pharmaceuticals, nutraceuticals, and telehealth, Cosmos Health is poised to play a pivotal role in addressing some of the most pressing health challenges of our time. As the world grapples with the emergence of new viral strains and the lingering effects of the COVID-19 pandemic, the importance of robust healthcare infrastructure and advanced diagnostic tools cannot be overstated.

In conclusion, the exclusive distribution rights secured by Cosmos Health for Virax Biolabs’ MPox virus Real-Time PCR detection kits mark a significant milestone in the company’s journey. This partnership not only enhances Cosmos Health’s portfolio but also underscores its commitment to public health and safety. As the company continues to innovate and expand its reach, it remains dedicated to providing high-quality healthcare solutions to meet the evolving needs of patients and healthcare providers worldwide.